If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor advisory service entitled Gastric Cancer, Decision Resources is offering an exclusive analyst call entitled Decision Reversed – After a Preliminary Negative Appraisal, NICE Endorses Herceptin for the Treatment of HER2-Positive Gastric Cancer. Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. Roche/Genentech/Chugai’s Herceptin became the first targeted therapy to significantly extend the survival of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) and, earlier this year, Herceptin gained European approval for this indication. In September, the National Institute for Health and Clinical Excellence (NICE) announced that Herceptin combined with standard doublet chemotherapy would be recommended for the first-line treatment of HER2-positive metastatic GC. Although NICE had given a preliminary negative appraisal of Herceptin in July 2010 on the grounds that the drug’s cost effectiveness was unclear in GC, the agency has now concluded that Herceptin’s use in a narrower definition of highly HER2-positive GC patients is cost-effective and has recommended Herceptin’s use for the indication. Due to the tight restrictions for eligibility of Herceptin in the United Kingdom, and the small number of eligible patients, sales of Herceptin in this country—approximately $6 million in 2019—will comprise only a small proportion of the overall forecasted sales of this agent in the world’s major pharmaceutical markets. Decision Resources forecasts that Herceptin will garner sales of $212 million in 2014 and $222 million in 2019. This 15-minute analyst call, presented by Decision Resources Analyst Rachel Webster, D.Phil., will answer the following questions:
Dr. Webster will conduct a live Q & A session after the presentation. Registration Decision Reversed – After a Preliminary Negative Appraisal, NICE Endorses Herceptin for the Treatment of HER2-Positive Gastric Cancer October 15, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-993-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Rachel Webster, M.Sc., D.Phil., is a research analyst in the oncology department at Decision Resources. Prior to joining the company, Dr. Webster was a research scientist at Immunocore (formerly MediGene) in the phage display and protein engineering group. Dr. Webster also worked at Cybersense Biosystems, where her research involved molecular engineering of bacterial membrane receptors and signal transduction pathways for the construction of a biosensor. Dr. Webster obtained her D.Phil. and M.Sc. in biological sciences from the University of Oxford..